Announcement

Date Time Subject
2024/12/0518:28:04PMC, a subsidiary of Medeon, announced the US Expander-2 Pivotal Study for its minimally invasive BPH treatment Urocross has completed the subject enrollment.
2024/11/1117:02:55The board of directors approved the establishment of Sustainable Development Committee.
2024/11/1116:56:23Medeon Board of Directors approved the 2024Q3 consolidated financial reports
2024/11/0117:11:42Announcement for the Board of Directors meeting date to approve the third-quarter 2024 financial report
2024/08/2114:51:52Medeon, on behalf of its subsidiary PMC, announces the board resolution of record date for the cash capital increase and other related matters
2024/08/2114:41:12Medeon, on behalf of its subsidiary PMC, announces the material resolutions at the 2024 the 1st Extraordinary Shareholders’ Meeting.
2024/08/1414:46:35Announcement of Supplementary Information on Climate-Related Content in the Company’s 2023 Annual Report
2024/08/0622:23:30Medeon, on behalf of its subsidiary PMC, announces the resolution of BOD on the issuance of Series D Preferred Stocks
2024/08/0616:21:28BOD of Medeon’s major subsidiary Prodeon resolved to convene the 2024 1st Extraordinary Shareholders’ Meeting for common and preferred shareholders.
2024/08/0616:10:32Medeon Board of Directors approved the 2024Q2 consolidated financial reports